Лики маниакально-депрессивного расстройства - Януш Рыбаковский
Шрифт:
Интервал:
Закладка:
219. Rybakowski J. The antidepressant effect of carbamazepine in callosal agenesis: a case report. Pharmacopsychiatry 1992; 25: 154–156.
220. Rybakowski J.K. Two generations of mood stabilizers. International Journal of Neuropsycho-pharmacology 2007; 10: 709–711.
221. Rybakowski J. Zaburzenia psychiczne w swietle koncepcji ewolucji i socjobiologii. In: Bili-kiewicz A, Puzynski S, Rybakowski J, Wciorka J. (eds.). Psychiatria. Tom 1. Wydawnictwo Medyczne Urban & Partner, Wroclaw, 2002: 224–234.
222. Rybakowski J.K., Amsterdam JD. Lithium prophylaxis and recurrent labial herpes infections. Lithium 1991; 2: 43–47.
223. Rybakowski J.K., Borkowska A, Czerski PM et al. Polymorphism of the brain-derived neu-rotrophic factor gene and performance on a cognitive prefrontal test in bipolar patients. Bipolar Disorders 2003; 5: 468–472.
224. Rybakowski J.K., Borkowska A, Skibinska M, Hauser J. Illness-specific association of val66met BDNF polymorphism with performance on Wisconsin Card Sorting Test in bipolar mood disorder. Molecular Psychiatry 2006; 11: 122–124.
225. Rybakowski J., Chlopocka-Wozniak M. Dlugotrwale stosowanie wçglanu litu – refleksje na podstawie przypadku 25-letniej profilaktyki litem. Psychiatria Polska 1996; 30: 731–740.
226. Rybakowski J., Chlopocka-Wozniak M., Kapelski Z. Ocena kliniczna skutecznosci profilaktycznej dlugotrwalego stosowania wçglanu litu u chorych z endogennymi zespolami depresyjnymi. Psychiatria Polska 1980; 14: 357–361.
227. Rybakowski J.K, Chlopocka-Wozniak M., Suwalska A. The prophylactic effect of long-term lithium administration in bipolar patients entering treatment in the 1970s and 1980s. Bipolar Disorders 2001; 3: 63–67.
228. Rybakowski J., Dudek D., Jaracz J. et al. Standardy leczenia chorob afektywnych. Farmakoterapia w Psychiatrii i Neurologii 2007; 23: 7-61.
229. Rybakowski J., Frazer A., Mendels J., Ramsey T.A. Erythrocyte accumulation of the lithium ion in control subjects and patients with primary affective disorder. Communications in Psycho-pharmacology 1978; 2: 99-104.
230. Rybakowski J., Matkowski K. Adding lithium to antidepressant therapy: factors related to therapeutic potentiation. European Neuropsychopharmacology 1992; 2: 161–165.
231. Rybakowski J., Matkowski K. Synergistyczne dzialanie litu i tymoleptykow w depresji endogennej. Psychiatria Polska 1987; 21: 115–120.
232. Rybakowski J.K., Suwalska A, Chlopocka-Wozniak M. Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression. Neuropsychobiology 1999; 40:134–139.
233. Rybakowski J.K., Suwalska A, Czerski PM et al. Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype. Pharmacological Report 2005; 57: 124–127.
234. Rybakowski J.K., Suwalska A, Lojko D et al. Bipolar mood disorders among Polish psychiatric outpatients treated for major depression. Journal of Affective Disorders 2005; 84: 141–147.
235. Rybakowski J.K., Suwalska A, Lojko D et al. Types of depression more frequent in bipolar than in unipolar affective illness: results of the Polish DEP-BI study. Psychopathology 2007; 40: 153–158.
236. Rybakowski J.K., Suwalska A, Skibinska M et al. Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry 2005; 38: 166–170.
237. Rybakowski J., Tuszewska M. Lithium or lamotrigine augmentation in treatment-resistant depression. International Journal of Neuropsychopharmacology 2006; 9 (Suppl 1): S232.
238. Rybakowski J.K., Twardowska K. The dexamethasone/corticotropin- releasing hormone test in depression in bipolar and unipolar affective illness. Journal of Psychiatric Research 1999; 33: 363–370.
239. Rybakowski J.K., Wykrçtowicz A, Heymann-Szlachcinska A, Wysocki H. Impairment of endo-thelial function in unipolar and bipolar depression. Biological Psychiatry 2006; 60: 889–891.
240. Sachar E.J., Hellman L., Roffwarg H.P. et al. Disrupted 24-hour patterns of cortisol secretion in psychotic depression. Archives of General Psychiatry 1973; 28: 19–24.
241. Saggese J., Lieberman D.Z., Goodwin F.K. The role of recurrence and cyclicity in differentiating mood disorder diagnoses. Primary Psychiatry 2006; 13: 43–48.
242. Sajatovic M., Valenstein M., Blow F. et al. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiatric Services 2007; 58: 855–863.
243. Santosa C.M., Strong C.M., Nowakowska C. et al. Enhanced creativity in bipolar disorder patients: a controlled study. Journal of Affective Disorders 2007; 100: 31–39.
244. Scheffer R.E. Concurrent ADHD and bipolar disorder. Current Psychiatry Reports 2007; 9: 415–419.
245. Schildkraut J.J. The catecholamine hypothesis of affective disorders: A review of the supporting evidence. American Journal of Psychiatry 1965; 122: 509–522.
246. Schildkraut J.J., Hirshfeld A.J., Murphy J.M. Mind and mood in modern art, II: Depressive disorders, spirituality, and early deaths in the abstract expressionist artists of the New York School. American Journal of Psychiatry 1994; 151: 482–488.
247. Schneider K. Klinische Psychopathologie. Georg Thieme Verlag, Stuttgart, 1950.
248. Schou M. Artistic productivity and lithium prophylaxis in manic-depressive illness. British Journal of Psychiatry 1979; 135: 97-103.
249. Schou M. Biology and the pharmacology of lithium ion. Pharmacological Reviews 1957; 9: 17–58.
250. Schou M. Lit w leczeniu chorob afektywnych. Instytut Psychiatrii i Neurologii, Warszawa, 2006.
251. Schou M, Juel-Nielsen N, Stromgren E, Voldby H. The treatment of manic psychoses by the administration of lithium salts. Journal of Neurology Neurosurgery and Psychiatry 1954; 17: 250–260.
252. Schou M., Thompsen K. Lithium prophylaxis of recurrent endogenous affective disorders. In: Johnson FN (eds.). Lithium Research and Therapy. Academic Press, London, 1976: 63–84.
253. Schuldberg D. Eysenck Personality Questionnaire scales and paper-and-pencil tests related to creativity. Psychological Report 2005; 97: 180–182.
254. Seeman P. Brain dopamine receptors. Pharmacological Reviews 1980; 32: 229–313.
255. Selye H. The Stress of Life. McGraw Hill, New York, 1956.
256. Serretti A., Lattuada E., Lorenzi C. et al. Dopamine receptor D2 Ser/Cys 311 variant is associated with delusion and disorganization symptomatology in major psychoses. Molecular Psychiatry 2000; 5: 270274.
257. Sharot T., Riccardi A.M., Raio C.M., Phelps E.A. Neural mechanisms mediating optimism bias. Nature 2007; publikacja internetowa z 24 pazdziernika (przed drukiem w kolejnym numerze pisma).
258. Shaw E.D., Mann J.J., Stokes P.E., Manevitz A.Z. Effects of lithium carbonate on associative productivity and idiosyncrasy in bipolar outpatients. American Journal of Psychiatry 1986; 143: 1166–1169.
259. Shorter E. The doctrine of the two depressions in historical perspective. Acta Psychiatrica Scandinavica 2007; 433: 5-13.
260. Skinner G.R., Hartley C., Buchan A. et al. The effect of lithium chloride on the replication of herpes simplex virus. Medical Microbiology and Immunology 1980; 168: 139–148.
261. Siowacki J. Anhelli. Universitas, Krakow, 2002.
262. Stuzewska A., Rybakowski J., Bosmans E. et al. Indicators of immune activation in major depression. Psychiatry Research 1996; 64: 161–167.
263. Soares J.C., Mallinger A.G. Intracellular phosphatidylinositol pathway abnormalities in bipolar disorder patients. Psychopharmacology Bulletin 1997; 33: 685–691.
264. Sophocles. Ajax. Cambridge University Press, Cambridge, 2001.
265. Starkstein S.E., Robinson R.G. Mechanism of disinhibition after brain lesions. Journal of Nervous and Mental Disease 1997; 185: 108–114.
266. Stevens A., Price J. Evolutionary Psychiatry: A New Beginning. Routledge, London, 1996.
267. Strakowski S.M., Adler C.M., DelBello M.P.
